Kinetics of serum amyloid protein A in casein-induced murine amyloidosis

Merrill Benson, M. A. Scheinberg, T. Shirahama, E. S. Cathcart, M. Skinner

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Serum amyloid protein A (SAA), the precursor of secondary amyloid protein, is elevated in chronic diseases which are associated with an increased incidence of amyloid. However, SAA is also elevated in acute bacterial and viral infections and some forms of cancer. The murine model of casein induced amyloidosis was studied to determine the relationship between SAA production and amyloid deposition. SAA levels measured by radioimmunoassay were found to be as high as 200 times the normal level in CBA/J mice receiving daily parenteral casein. After a single injection of casein the SAA level was elevated by 3 hr and peaked by 12-18 hr. Similar levels were found in casein treated A/J mice, a strain less susceptible to the induction of amyloid. Parenterally administered bovine serum albumin, which has low potential for amyloid induction, gave SAA levels in CBA/J and A/J mice comparable to casein treatment. These data show that, while SAA levels are elevated during chronic antigenic stimulation, there are other factors involved in amyloid formation. These factors may include alterations in the degradation of SAA by the reticuloendothelial system caused by substances such as casein. Nude (athymic) mice were shown to attain high levels of SAA after receiving casein parenterally. Therefore thymus derived lymphocytes are not necessary for the synthesis of SAA.

Original languageEnglish (US)
Pages (from-to)412-417
Number of pages6
JournalJournal of Clinical Investigation
Volume59
Issue number3
StatePublished - 1977
Externally publishedYes

Fingerprint

Serum Amyloid A Protein
Amyloidosis
Caseins
Amyloid
Nude Mice
Amyloidogenic Proteins
Inbred CBA Mouse
Mononuclear Phagocyte System
Amyloid beta-Protein Precursor
Virus Diseases
Bovine Serum Albumin
Bacterial Infections
Thymus Gland
Radioimmunoassay
Blood Proteins
Chronic Disease
Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Benson, M., Scheinberg, M. A., Shirahama, T., Cathcart, E. S., & Skinner, M. (1977). Kinetics of serum amyloid protein A in casein-induced murine amyloidosis. Journal of Clinical Investigation, 59(3), 412-417.

Kinetics of serum amyloid protein A in casein-induced murine amyloidosis. / Benson, Merrill; Scheinberg, M. A.; Shirahama, T.; Cathcart, E. S.; Skinner, M.

In: Journal of Clinical Investigation, Vol. 59, No. 3, 1977, p. 412-417.

Research output: Contribution to journalArticle

Benson, M, Scheinberg, MA, Shirahama, T, Cathcart, ES & Skinner, M 1977, 'Kinetics of serum amyloid protein A in casein-induced murine amyloidosis', Journal of Clinical Investigation, vol. 59, no. 3, pp. 412-417.
Benson M, Scheinberg MA, Shirahama T, Cathcart ES, Skinner M. Kinetics of serum amyloid protein A in casein-induced murine amyloidosis. Journal of Clinical Investigation. 1977;59(3):412-417.
Benson, Merrill ; Scheinberg, M. A. ; Shirahama, T. ; Cathcart, E. S. ; Skinner, M. / Kinetics of serum amyloid protein A in casein-induced murine amyloidosis. In: Journal of Clinical Investigation. 1977 ; Vol. 59, No. 3. pp. 412-417.
@article{da3f57c053f04fee88acfe4b2073b2c4,
title = "Kinetics of serum amyloid protein A in casein-induced murine amyloidosis",
abstract = "Serum amyloid protein A (SAA), the precursor of secondary amyloid protein, is elevated in chronic diseases which are associated with an increased incidence of amyloid. However, SAA is also elevated in acute bacterial and viral infections and some forms of cancer. The murine model of casein induced amyloidosis was studied to determine the relationship between SAA production and amyloid deposition. SAA levels measured by radioimmunoassay were found to be as high as 200 times the normal level in CBA/J mice receiving daily parenteral casein. After a single injection of casein the SAA level was elevated by 3 hr and peaked by 12-18 hr. Similar levels were found in casein treated A/J mice, a strain less susceptible to the induction of amyloid. Parenterally administered bovine serum albumin, which has low potential for amyloid induction, gave SAA levels in CBA/J and A/J mice comparable to casein treatment. These data show that, while SAA levels are elevated during chronic antigenic stimulation, there are other factors involved in amyloid formation. These factors may include alterations in the degradation of SAA by the reticuloendothelial system caused by substances such as casein. Nude (athymic) mice were shown to attain high levels of SAA after receiving casein parenterally. Therefore thymus derived lymphocytes are not necessary for the synthesis of SAA.",
author = "Merrill Benson and Scheinberg, {M. A.} and T. Shirahama and Cathcart, {E. S.} and M. Skinner",
year = "1977",
language = "English (US)",
volume = "59",
pages = "412--417",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - Kinetics of serum amyloid protein A in casein-induced murine amyloidosis

AU - Benson, Merrill

AU - Scheinberg, M. A.

AU - Shirahama, T.

AU - Cathcart, E. S.

AU - Skinner, M.

PY - 1977

Y1 - 1977

N2 - Serum amyloid protein A (SAA), the precursor of secondary amyloid protein, is elevated in chronic diseases which are associated with an increased incidence of amyloid. However, SAA is also elevated in acute bacterial and viral infections and some forms of cancer. The murine model of casein induced amyloidosis was studied to determine the relationship between SAA production and amyloid deposition. SAA levels measured by radioimmunoassay were found to be as high as 200 times the normal level in CBA/J mice receiving daily parenteral casein. After a single injection of casein the SAA level was elevated by 3 hr and peaked by 12-18 hr. Similar levels were found in casein treated A/J mice, a strain less susceptible to the induction of amyloid. Parenterally administered bovine serum albumin, which has low potential for amyloid induction, gave SAA levels in CBA/J and A/J mice comparable to casein treatment. These data show that, while SAA levels are elevated during chronic antigenic stimulation, there are other factors involved in amyloid formation. These factors may include alterations in the degradation of SAA by the reticuloendothelial system caused by substances such as casein. Nude (athymic) mice were shown to attain high levels of SAA after receiving casein parenterally. Therefore thymus derived lymphocytes are not necessary for the synthesis of SAA.

AB - Serum amyloid protein A (SAA), the precursor of secondary amyloid protein, is elevated in chronic diseases which are associated with an increased incidence of amyloid. However, SAA is also elevated in acute bacterial and viral infections and some forms of cancer. The murine model of casein induced amyloidosis was studied to determine the relationship between SAA production and amyloid deposition. SAA levels measured by radioimmunoassay were found to be as high as 200 times the normal level in CBA/J mice receiving daily parenteral casein. After a single injection of casein the SAA level was elevated by 3 hr and peaked by 12-18 hr. Similar levels were found in casein treated A/J mice, a strain less susceptible to the induction of amyloid. Parenterally administered bovine serum albumin, which has low potential for amyloid induction, gave SAA levels in CBA/J and A/J mice comparable to casein treatment. These data show that, while SAA levels are elevated during chronic antigenic stimulation, there are other factors involved in amyloid formation. These factors may include alterations in the degradation of SAA by the reticuloendothelial system caused by substances such as casein. Nude (athymic) mice were shown to attain high levels of SAA after receiving casein parenterally. Therefore thymus derived lymphocytes are not necessary for the synthesis of SAA.

UR - http://www.scopus.com/inward/record.url?scp=0017603079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017603079&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 412

EP - 417

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -